Circulating adhesion molecules in the critically ill: a comparison between trauma and sepsis patients.
OBJECTIVE
The time course of circulating adhesion molecules was monitored in traumatized and sepsis patients.


METHODS
Prospective, descriptive.


METHODS
A surgical intensive care unit of a university hospital.


METHODS
A total of 30 consecutive critically ill patients suffering either from trauma (n = 15) or postoperative sepsis (n = 15).


METHODS
All patients were on continuous analgo-sedation and mechanical ventilation.


RESULTS
From arterial blood samples, plasma levels of soluble adhesion molecules [endothelial leukocyte adhesion molecules (sELAM-1), intercellular adhesion molecule-1 (sICAM-1)], and vascular cell adhesion molecule-1 (sVCAM-1) were measured on the day of admission (trauma patients) or on the day of diagnosis of sepsis (= baseline values), and during the following 5 days. In the trauma group, sELAM-1 (57.9 +/- 11.0 ng/ml) and sVCAM-1 (698 +/- 93 ng/ml) were within normal ranges at baseline, whereas they were markedly elevated in the sepsis group (sELAM-1: 340 +/- 95 ng/ml; sVCAM-1; 1,042 +/- 449 ng/ml). In the sepsis patients, sELAM-1 significantly decreased and sVCAM-1 increased, but remained almost unchanged in the trauma patients. Non-survivors showed markedly elevated plasma levels of sELAM-1 and sVCAM-1. sICAM-1 was elevated in both groups at baseline and was higher in the sepsis group (1,266 +/- 261 ng/ml) than in the trauma group. In the septic patients, sICAM-1 increased further (2,022 +/- 609 ng/ml) and remained unchanged in the trauma group. All non-survivors showed sICAM-1 plasma levels of > 800 ng/ml.


CONCLUSIONS
Endothelial damage may result in multiple-organ dysfunction syndrome. Adhesion molecules are considered to be a cornerstone in this process. Trauma patients showed lower plasma levels of circulating adhesion molecules than did sepsis patients indicating more pronounced (inflammatory related) endothelial activation or damage in sepsis. Therapeutic modulation of circulating adhesion molecules may be of benefit to the patients outcome and therefore warrants further study.
Boldt
J
J
Klinikum der Stadt Ludwigshafen, Anesthesiology and Intensive Care Medicine, Germany.
Muller
M
M
Kuhn
D
D
Linke
L C
LC
Hempelmann
G
G
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001158:Arteries; D003131:Combined Modality Therapy; D016638:Critical Illness; D019040:E-Selectin / Q000097:blood*; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D018805:Sepsis / Q000097:blood* / Q000628:therapy; D013997:Time Factors; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood*; D014947:Wounds and Injuries / Q000097:blood* / Q000628:therapy
D019040:E-Selectin; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1